-transparent.png){kind=logo}
In four patients with Parkinson disease, we compared carbidopa combined with levodopa (Sinemet) and benserazide combined with levodopa (Madopar). All of these patients had responded to treatment, first with levodopa and then with Sinemet; after 6 years two continued to show a good response, while two developed marked "on-off" phenomena. Clinically, Sinemet and Madopar were similar; however, DOPA levels were higher, but with a shorter half-life, on Madopar. The higher DOPA levels may have been offset by the shorter half-life, resulting in no clinical change. DOPA levels were lower and half-life was shorter in patients with on-off phenomena. These differences may be responsible in part for the on-off phenomena.
A Lieberman, and
E Estey, and
G Gopinathan, and
T Ohashi, and
A Sauter, and
M Goldstein
April 1972,
The Journal of pharmacy and pharmacology,
A Lieberman, and
E Estey, and
G Gopinathan, and
T Ohashi, and
A Sauter, and
M Goldstein
May 1969,
The Journal of pharmacy and pharmacology,
A Lieberman, and
E Estey, and
G Gopinathan, and
T Ohashi, and
A Sauter, and
M Goldstein
February 1974,
Ugeskrift for laeger,
A Lieberman, and
E Estey, and
G Gopinathan, and
T Ohashi, and
A Sauter, and
M Goldstein
May 1973,
Lancet (London, England),
A Lieberman, and
E Estey, and
G Gopinathan, and
T Ohashi, and
A Sauter, and
M Goldstein
November 1983,
Pediatric research,
A Lieberman, and
E Estey, and
G Gopinathan, and
T Ohashi, and
A Sauter, and
M Goldstein
November 1974,
British medical journal,
A Lieberman, and
E Estey, and
G Gopinathan, and
T Ohashi, and
A Sauter, and
M Goldstein
December 1981,
Italian journal of neurological sciences,
A Lieberman, and
E Estey, and
G Gopinathan, and
T Ohashi, and
A Sauter, and
M Goldstein
March 1966,
Pharmacological reviews,
A Lieberman, and
E Estey, and
G Gopinathan, and
T Ohashi, and
A Sauter, and
M Goldstein
April 1971,
Physiology & behavior,
A Lieberman, and
E Estey, and
G Gopinathan, and
T Ohashi, and
A Sauter, and
M Goldstein
January 1972,
Psychopharmacologia,
